Obesity and pancreatitis

Biswajit Khatua, Bara El-Kurdi, Vijay Prem Singh

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Purpose of review: The obesity pandemic poses a unique set of problems for acute pancreatitis - both by increasing acute pancreatitis incidence, and worsening acute pancreatitis severity. This review explores these associations, underlying mechanisms, and potential therapies. Recent findings: We review how the obesity associated increase in gallstones, surgical, and endoscopic interventions for obesity management, diabetes, and related medications such as incretin-based therapies and hypertriglyceridemia may increase the incidence of acute pancreatitis. The mechanism of how obesity may increase acute pancreatitis severity are discussed with a focus on cytokines, adipokines, damage-associated molecular patterns and unsaturated fatty acid-mediated lipotoxicity. The role of obesity in exacerbating pancreatic necrosis is discussed; focusing on obesity-associated pancreatic steatosis. We also discuss how peripancreatic fat necrosis worsens organ failure independent of pancreatic necrosis. Last, we discuss emerging therapies including choice of intravenous fluids and the use of lipase inhibitors which have shown promise during severe acute pancreatitis. Summary: We discuss how obesity may contribute to increasing acute pancreatitis incidence, the role of lipolytic unsaturated fatty acid release in worsening acute pancreatitis, and potential approaches, including appropriate fluid management and lipase inhibition in improving acute pancreatitis outcomes.

Original languageEnglish (US)
Pages (from-to)374-382
Number of pages9
JournalCurrent Opinion in Gastroenterology
Volume33
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Pancreatitis
Obesity
Lipase
Unsaturated Fatty Acids
Incidence
Necrosis
Fat Necrosis
Incretins
Adipokines
Hypertriglyceridemia
Gallstones
Pandemics
Therapeutics
Cytokines

Keywords

  • lipase inhibition
  • obesity
  • pancreatitis
  • unsaturated fatty acids

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Obesity and pancreatitis. / Khatua, Biswajit; El-Kurdi, Bara; Singh, Vijay Prem.

In: Current Opinion in Gastroenterology, Vol. 33, No. 5, 01.09.2017, p. 374-382.

Research output: Contribution to journalReview article

Khatua, Biswajit ; El-Kurdi, Bara ; Singh, Vijay Prem. / Obesity and pancreatitis. In: Current Opinion in Gastroenterology. 2017 ; Vol. 33, No. 5. pp. 374-382.
@article{a2472e9bc4344145ae38fdfca192d193,
title = "Obesity and pancreatitis",
abstract = "Purpose of review: The obesity pandemic poses a unique set of problems for acute pancreatitis - both by increasing acute pancreatitis incidence, and worsening acute pancreatitis severity. This review explores these associations, underlying mechanisms, and potential therapies. Recent findings: We review how the obesity associated increase in gallstones, surgical, and endoscopic interventions for obesity management, diabetes, and related medications such as incretin-based therapies and hypertriglyceridemia may increase the incidence of acute pancreatitis. The mechanism of how obesity may increase acute pancreatitis severity are discussed with a focus on cytokines, adipokines, damage-associated molecular patterns and unsaturated fatty acid-mediated lipotoxicity. The role of obesity in exacerbating pancreatic necrosis is discussed; focusing on obesity-associated pancreatic steatosis. We also discuss how peripancreatic fat necrosis worsens organ failure independent of pancreatic necrosis. Last, we discuss emerging therapies including choice of intravenous fluids and the use of lipase inhibitors which have shown promise during severe acute pancreatitis. Summary: We discuss how obesity may contribute to increasing acute pancreatitis incidence, the role of lipolytic unsaturated fatty acid release in worsening acute pancreatitis, and potential approaches, including appropriate fluid management and lipase inhibition in improving acute pancreatitis outcomes.",
keywords = "lipase inhibition, obesity, pancreatitis, unsaturated fatty acids",
author = "Biswajit Khatua and Bara El-Kurdi and Singh, {Vijay Prem}",
year = "2017",
month = "9",
day = "1",
doi = "10.1097/MOG.0000000000000386",
language = "English (US)",
volume = "33",
pages = "374--382",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Obesity and pancreatitis

AU - Khatua, Biswajit

AU - El-Kurdi, Bara

AU - Singh, Vijay Prem

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose of review: The obesity pandemic poses a unique set of problems for acute pancreatitis - both by increasing acute pancreatitis incidence, and worsening acute pancreatitis severity. This review explores these associations, underlying mechanisms, and potential therapies. Recent findings: We review how the obesity associated increase in gallstones, surgical, and endoscopic interventions for obesity management, diabetes, and related medications such as incretin-based therapies and hypertriglyceridemia may increase the incidence of acute pancreatitis. The mechanism of how obesity may increase acute pancreatitis severity are discussed with a focus on cytokines, adipokines, damage-associated molecular patterns and unsaturated fatty acid-mediated lipotoxicity. The role of obesity in exacerbating pancreatic necrosis is discussed; focusing on obesity-associated pancreatic steatosis. We also discuss how peripancreatic fat necrosis worsens organ failure independent of pancreatic necrosis. Last, we discuss emerging therapies including choice of intravenous fluids and the use of lipase inhibitors which have shown promise during severe acute pancreatitis. Summary: We discuss how obesity may contribute to increasing acute pancreatitis incidence, the role of lipolytic unsaturated fatty acid release in worsening acute pancreatitis, and potential approaches, including appropriate fluid management and lipase inhibition in improving acute pancreatitis outcomes.

AB - Purpose of review: The obesity pandemic poses a unique set of problems for acute pancreatitis - both by increasing acute pancreatitis incidence, and worsening acute pancreatitis severity. This review explores these associations, underlying mechanisms, and potential therapies. Recent findings: We review how the obesity associated increase in gallstones, surgical, and endoscopic interventions for obesity management, diabetes, and related medications such as incretin-based therapies and hypertriglyceridemia may increase the incidence of acute pancreatitis. The mechanism of how obesity may increase acute pancreatitis severity are discussed with a focus on cytokines, adipokines, damage-associated molecular patterns and unsaturated fatty acid-mediated lipotoxicity. The role of obesity in exacerbating pancreatic necrosis is discussed; focusing on obesity-associated pancreatic steatosis. We also discuss how peripancreatic fat necrosis worsens organ failure independent of pancreatic necrosis. Last, we discuss emerging therapies including choice of intravenous fluids and the use of lipase inhibitors which have shown promise during severe acute pancreatitis. Summary: We discuss how obesity may contribute to increasing acute pancreatitis incidence, the role of lipolytic unsaturated fatty acid release in worsening acute pancreatitis, and potential approaches, including appropriate fluid management and lipase inhibition in improving acute pancreatitis outcomes.

KW - lipase inhibition

KW - obesity

KW - pancreatitis

KW - unsaturated fatty acids

UR - http://www.scopus.com/inward/record.url?scp=85024503677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024503677&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000386

DO - 10.1097/MOG.0000000000000386

M3 - Review article

C2 - 28719397

AN - SCOPUS:85024503677

VL - 33

SP - 374

EP - 382

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 5

ER -